• Home
  • About Us
  • Blog
  • Contact Us

Pulmonary Hypertension RN

  • What is Pulmonary Hypertension?
    • What is Pulmonary Hypertension?
    • Pulmonary Hypertension Symptoms
    • Types of Pulmonary Hypertension
    • Causes of Pulmonary Hypertension
    • PH vs. PAH
    • Diastolic Heart Failure vs. PAH
    • WHO Group 3 Pulmonary Hypertension, IPF & COPD
    • Pulmonary Veno-Occlusive Disease
    • Hereditary Hemorrhagic Telangiectasia (HHT)
      • Hereditary Hemorrhagic Telangiectasia (HHT) Treatment
    • Functional Classification of Pulmonary Hypertension
    • Pediatric Pulmonary Arterial Hypertension
    • Sickle Cell and Pulmonary Hypertension
    • Stimulant Associated Pulmonary Arterial Hypertension
    • Research, Life Expectancy & Prognosis for PH
  • Diagnosing & Monitoring PAH
    • Pulmonary Arterial Hypertension Diagnosis
    • How Am I Doing? Assessing Your PAH.
    • Blood Tests
    • Cardiopulmonary Exercise Test (CPET)
    • CT (Computed Tomography) Scan
    • Echocardiogram: An Overview
    • Echocardiogram: A Detailed Look
    • Pulmonary Function Tests (PFTs)
    • Right Heart Catheterization
    • Six Minute Walk
    • Ventilation Perfusion Scan (VQ Scan)
    • CTEPH
      • CTEPH: WHO Group 4 Pulmonary Hypertension
      • PTE (Pulmonary Thromboendarterectomy) Surgery
      • Adempas used to Treat PAH and CTEPH
  • PAH Treatment
    • Pulmonary Hypertension Centers
    • Pulmonary Hypertension Treatments
    • Continuously Infused Therapies Used to Treat PH
    • Prostanoids for Treatment of PH
    • Adcirca and Revatio Used to Treat Pulmonary Arterial Hypertension (PAH)
    • Adempas used to Treat PAH and CTEPH
    • Tracleer, Letairis, and Opsumit Treatments
    • Uptravi is Approved for PAH Treatment
    • Oxygen Therapy for Pulmonary Hypertension
    • Salt and Water Restrictions
    • Exercise & PAH
    • Diuretics
    • Blood Thinners
    • Getting the Most Out of PAH Therapy
      • Letairis
      • Opsumit
      • Sildenafil (Revatio)
  • Congenital Heart Disease
    • Eisenmenger’s Syndrome
    • Update on Management of PAH-CHD
    • Congenital Heart Disease & Sleep Apnea
    • Complex Congenital Heart Disease
    • Atrial Septal Defect and Pulmonary Arterial Hypertension
  • FAQ’s
    • Implanted Remodulin Pump, Right Heart Catheterization, PAH & Pregnancy
    • Oral Treatments, Care Centers & Hole in Heart
    • FAQ’s: Altitude, Cold & Allergy Medications
    • FAQ’s: Psoriasis, Idiopathic PAH, Contraceptives & PAH
    • FAQ’s: Causes of Pulmonary Hypertension, Symptom Frequency & Care Centers
    • FAQ: PAH Experts, Pregnancy, Mild PAH & Vacationing
    • FAQ’s: CTEPH, Blood Clots, Corrective Surgery & PAH Care Centers
    • FAQ’s: VQ Scans & PAH Curable?
    • FAQ’s: Mild Pulmonary Hypertension?
    • FAQ’s: Boating, Swimming & Eating with PAH

Phase 1 Study of Stem Cells for Pulmonary Arterial Hypertension

July 18, 2019 By Dr. Jeremy Feldman

researching stem cells to treat PAH

Stem cells are special types of cells that have the ability to renew themselves and develop into different types of tissues.  There are a variety of different types of stem cells but the general concept is that we all have a small reservoir of these cells in our bodies.  These cells allow us to repair and replenish the cells that make up the different tissues in our body.  For example, bone marrow stem cells allow our bone marrow to keep producing all the cells in our blood.  Mesenchymal stem cells reside in the different tissues and help repair and replace damaged cells and tissues.  Stem cells can give rise to progenitor cells.  These cells have lost the ability to self-renew and are only able to develop into certain types of tissues.  

The PHACet Study

To date we have had only a single study completed using stem cells to treat PAH.  The PHACet Study included 7 patients who were given three infusions of stem cells into their heart (right atrium).  This study did not look at long term changes in pulmonary artery pressure or right heart function and there was no control (or comparison) group.  They were able to show increased six-minute walk distance at six months compared to the start of the study.  One of the seven patients died shortly after receiving the stem cell infusion. 

Cedars-Sinai in Los Angles has started a phase 1 clinical trial using stem cells derived from heart tissue. Dr. Marban who is the head of Cedars-Sinai’s Heart Institute developed the technology to create the stem cells and has licensed it to Capricor who is sponsoring the study.  

Phase 1 studies are the very earliest clinical trials in humans.  These early studies are not looking at efficacy but rather focused on whether the intervention is safe.  Remember that there is no guarantee that stem cell therapy will be safe or effective.  The mortality rate in the PHACet study was 14% (1/7 patients died during the study). We are very excited about this phase 1 trial but the journey from a phase 1 study to a proven effective therapy takes many years and the odds are long that any one therapy will become a successful approved treatment.   

Beware of Scams

In contrast to the Cedars-Sinai study there are many scammers in the community preying on desperate PAH patients.  Buying a “stem cell” infusion for a discount price of $10-15,000 is not a great deal. You are gambling with your health.  The FDA has issued strong warnings against using these fake treatments. Not only are they not effective, they are potentially dangerous.   In America, real medical treatments have to go through a long process showing efficacy and safety.  Remember too that you will never be asked to pay to participate in a research trial.

Stay tuned for more information about Stem Cells and PAH.

Filed Under: Pulmonary Hypertension Treatments

Advertisement

PAH Life Expectancy

PAH Research

Research, Life Expectancy & Prognosis for PH

Major Developments in Pulmonary Hypertension Affecting Prognosis 1.     Approval of

Advertisement

Where to Get Treatment?

CCCs for PAH

Pulmonary Hypertension Centers

Where to get treatment for pulmonary hypertension? Pulmonary arterial hypertension is a

Popular Posts

PAH Expert talking with PH patient

Second Opinions

By Dr. Jeremy Feldman

I can’t tell you how frequently my patients ask if their doctor will be offended if the patient goes to a different

PAH treatment team

Who’s Who at your Pulmonary Hypertension Center

By Dr. Jeremy Feldman

The first visit at a PH center can be very overwhelming. Many patients receive the news that they have a serious life

The Doctor is In

  • Facebook
  • Google+
  • RSS
  • Twitter

Get Our Newsletter!

good news in pah

Recent Blog Posts

  • Pulmonary Hypertension Due To Valvular Heart Disease October 29, 2019
  • A New Approach to Treating Pulmonary Arterial Hypertension October 23, 2019
  • Scleroderma: Screening for Pulmonary Hypertension October 10, 2019

Categories

Archives

Copyright © 2019 Inspire Pulmonary Media, LLC